Publications by authors named "Anton Hagenbeek"

66Publications

Here to Stay: Biosimilars in Hematology.

Hemasphere 2019 Dec 19;3(6):e323. Epub 2019 Nov 19.

Department of Hematology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/HS9.0000000000000323DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924553PMC
December 2019

Untire: an all-embracing self-management eHealth program to cope with cancer-related fatigue.

Ecancermedicalscience 2018 20;12:ed81. Epub 2018 Mar 20.

Academic Medical Center, Department of Hematology, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3332/ecancer.2018.ed81DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880226PMC
March 2018

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.

J Clin Oncol 2017 Feb 28;35(5):544-551. Epub 2016 Dec 28.

Gustaaf W. van Imhoff, University Medical Center, University of Groningen; Bronno van der Holt, University Medical Center, Rotterdam; Anton Hagenbeek, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Andrew McMillan, Nottingham University Hospital, Nottingham; John Radford and Kirit M. Ardeshna, Christie Hospital NHS Trust, Manchester; Andrew Davies, University of Southampton, Southampton, United Kingdom; Matthew J. Matasar, Memorial Sloan Kettering Cancer Center, New York, NY; Kazimierz Kuliczkowski, Wroclaw Medical University, Wroclaw, Poland; WonSeog Kim, Sungkyunkwan University School of Medicine, Seoul, Korea; Xiaonan Hong, Fudan University, Shanghai, China; Jette Soenderskov Goerloev, Rigshospitalet; Steen Lisby, Genmab A/S, Copenhagen, Denmark; María Dolores Caballero Barrigón, Hospital Universitario de Salamanca, Salamanca, Spain; Michinori Ogura, Nagoya Daini Red Cross Hospital, Nagoya; Michinori Ogura, Tokai Central Hospital, Kakamigahara, Japan; Sirpa Leppä, Helsinki University Central Hospital Cancer Center, Helsinki, Finland; and Michael Fennessy and Qiming Liao, Novartis AG, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.0198DOI Listing
February 2017

Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.

J Clin Oncol 2017 Feb 28;35(5):552-560. Epub 2016 Dec 28.

Qian Shi and Daniel J. Sargent, Mayo Clinic, Rochester; Bruce A. Peterson, University of Minnesota, Minneapolis, MN; Christopher R. Flowers, Winship Cancer Institute of Emory University, Atlanta, GA; Wolfgang Hiddemann and Eva Hoster, Ludwig-Maximilians University Hospital, Munich; Michael Herold, HELIOS Kliniken, Erfurt, Germany; Robert Marcus, Addenbrooke's Hospital, Cambridge, United Kingdom; Anton Hagenbeek, Academic Medical Center, Amsterdam, the Netherlands; Eva Kimby, Karolinska Institutet, Stockholm, Sweden; Howard Hochster, Yale Cancer Center, New Haven, CT; Umberto Vitolo, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin; Marco Ladetto, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy; Emmanuel Gyan, University Hospital, Tours; Franck Morschhauser, Service Université de Lille 2, Lille; Gilles Salles, Université Claude Bernard, Pierre Bénite, France; Michele Ghielmini and Emanuele Zucca, Oncology Institute of Southern Switzerland, Bellinzona; Michele Ghielmini and Emanuele Zucca, Swiss Group for Clinical Cancer Research, Bern; Tina Nielsen, F. Hoffmann-La Roche, Basel; Sabine De Bedout, Celgene, Boudry, Switzerland; Tommy Fu, Celgene, Summit, NJ; Nancy Valente, Genentech, South San Francisco, CA; and Nathan H. Fowler, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.8651DOI Listing
February 2017

Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis.

J Clin Pharmacol 2014 Jul 28;54(7):818-27. Epub 2014 Jan 28.

Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, Research Triangle Park, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.268DOI Listing
July 2014

Optimising the lymphoma response criteria in the era of targeted therapy.

Lancet Oncol 2011 Jul 12;12(7):616-7. Epub 2011 Jun 12.

Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(11)70132-2DOI Listing
July 2011

Novel antibodies against follicular non-Hodgkin's lymphoma.

Best Pract Res Clin Haematol 2011 Jun 5;24(2):231-56. Epub 2011 May 5.

Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2011.03.002DOI Listing
June 2011

Preface on follicular non-Hodgkin's lymphoma.

Authors:
Anton Hagenbeek

Best Pract Res Clin Haematol 2011 Jun 6;24(2):93. Epub 2011 May 6.

Academic Medical Center, Department of Hematology, University of Amsterdam, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2011.03.009DOI Listing
June 2011

Diversity in antibody-based approaches to non-Hodgkin lymphoma.

Leuk Lymphoma 2010 Aug;51 Suppl 1:20-7

Fred Hutchinson Cancer Research Center, Division of Oncology, University of Washington, Seattle, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2010.500047DOI Listing
August 2010

CD20-targeted therapy: the next generation of antibodies.

Semin Hematol 2010 Apr;47(2):199-210

Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00371963100000
Publisher Site
http://dx.doi.org/10.1053/j.seminhematol.2010.01.007DOI Listing
April 2010

Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma.

J Clin Oncol 2009 Dec 26;27(36):6094-100. Epub 2009 Oct 26.

Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, 45 Little Britain, London EC1A 7BE, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.22.6258DOI Listing
December 2009

Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.

J Nucl Med 2009 Nov 16;50(11):1837-43. Epub 2009 Oct 16.

Department of Nuclear Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.109.067587DOI Listing
November 2009

Biomarkers and prognosis in malignant lymphomas.

Clin Lymphoma Myeloma 2009 Apr;9(2):160-6

Department of Hematology, Academic Medical Center, University of Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLM.2009.n.038DOI Listing
April 2009

Maintenance or eradication of residual disease in indolent lymphoma: where do we stand?

Authors:
Anton Hagenbeek

J Clin Oncol 2009 Apr 2;27(10):1540-2. Epub 2009 Mar 2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.19.8457DOI Listing
April 2009

High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.

Br J Haematol 2009 Feb 26;144(4):524-30. Epub 2008 Nov 26.

Department of Haematology, Erasmus Medical Centre, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2008.07498.xDOI Listing
February 2009

B-cell involvement in chronic graft-versus-host disease.

Haematologica 2008 Nov 25;93(11):1702-11. Epub 2008 Aug 25.

Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.13311DOI Listing
November 2008

Quantitative assessment of human T lymphocytes in RAG2(-/-)gammac(-/-) mice: the impact of ex vivo manipulation on in vivo functionality.

Exp Hematol 2007 Jan;35(1):117-27

Jordan Laboratory for Hemato-Oncology, Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2006.09.018DOI Listing
January 2007

Towards immunogene therapy of hematological malignancies.

Exp Hematol 2006 Mar;34(3):251-63

Jordan Laboratory for Haemato-Oncology, Department of Haematology, University Medical Centre Utrecht, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2005.10.004DOI Listing
March 2006

Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma.

Haematologica 2005 Oct;90(10):1422-32

Institute for Medical Technology Assessment, Department of Health Policy and Management, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
October 2005

UTY-specific TCR-transfer generates potential graft-versus-leukaemia effector T cells.

Br J Haematol 2005 May;129(3):392-402

Jordan Laboratory for Haemato-Oncology, Department of Haematology, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2141.2005.05461.xDOI Listing
May 2005

Future trends in radioimmunotherapy.

Authors:
Anton Hagenbeek

Semin Oncol 2005 Feb;32(1 Suppl 1):S57-62

Department of Hematology, University Medical Center, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2005.01.015DOI Listing
February 2005

Identification of a 40S ribosomal protein S4-derived H-Y epitope able to elicit a lymphoblast-specific cytotoxic T lymphocyte response.

Clin Cancer Res 2005 Mar;11(5):1694-703

Jordan Laboratory for Hemato-oncology, Department of Hematology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-1772DOI Listing
March 2005

Economic assessment in the management of non-Hodgkin's lymphoma.

Expert Opin Pharmacother 2004 Dec;5(12):2529-48

University Medical Centre Rotterdam, Erasmus MC, Institute for Medical Technology Assessment, PO Box 1738, 3000 DR Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.5.12.2529DOI Listing
December 2004

Enhanced engraftment of human cells in RAG2/gammac double-knockout mice after treatment with CL2MDP liposomes.

Exp Hematol 2004 Nov;32(11):1118-25

Department of Haematology, Jordan Laboratory, University Medical Center Utrecht, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2004.08.002DOI Listing
November 2004

Enhanced engraftment of human cells in RAG2/gammac double-knockout mice after treatment with CL2MDP liposomes.

Exp Hematol 2004 Nov;32(11):1118-25

Department of Haematology, Jordan Laboratory, University Medical Center Utrecht, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2004.08.002DOI Listing
November 2004

Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice.

Authors:
Anton Hagenbeek

Leuk Lymphoma 2003 ;44 Suppl 4:S37-47

Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190310001616944DOI Listing
June 2004

A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma.

Hematol J 2003 ;4(6):399-409

Erasmus Medical Center, University Medical Center, Institute for Medical Technology Assessment, Department of Health Policy and Management, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.thj.6200323DOI Listing
February 2004

Minimal residual disease in lymphoma revisited.

Authors:
Anton Hagenbeek

Clin Lymphoma 2003 Jun;4(1)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/clm.2003.n.009DOI Listing
June 2003

HLA-DRB1*16-restricted recognition of myeloid cells, including CD34+ CML progenitor cells.

Br J Haematol 2003 Jun;121(5):721-9

Jordan Laboratory for Haemato-Oncology, Department of Haematology, University Medical Centre Utrecht, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.1365-2141.2003.04341.xDOI Listing
June 2003

Development and application of quantitative real time PCR and RT-PCR assays that discriminate between the full-length and truncated herpes simplex virus thymidine kinase gene.

J Virol Methods 2003 May;109(2):177-86

Jordan Laboratory for Hemato-Oncology, Department of Hematology, Rm G.03.647, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0166-0934(03)00069-7DOI Listing
May 2003

Rituximab therapy for indolent non-Hodgkin's lymphoma.

Anticancer Drugs 2002 Nov;13 Suppl 2:S11-7

University Medical Center Utrecht, Department of Hematology, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
November 2002

Rituximab therapy for indolent non-Hodgkin's lymphoma.

Anticancer Drugs 2002 Nov;13 Suppl 2:S11-7

University Medical Center Utrecht, Department of Hematology, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
November 2002

Rituximab therapy for indolent non-Hodgkin's lymphoma.

Anticancer Drugs 2002 Nov;13 Suppl 2:S11-7

University Medical Center Utrecht, Department of Hematology, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
November 2002